Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
Genmab
University of Chicago
Genmab
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
AstraZeneca
Eli Lilly and Company
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Indapta Therapeutics, INC.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ascentage Pharma Group Inc.
MingSight Pharmaceuticals, Inc
Aprea Therapeutics
M.D. Anderson Cancer Center
Altor BioScience
City of Hope Medical Center
Alexion Pharmaceuticals, Inc.
National Cancer Institute (NCI)
AbbVie
Mayo Clinic
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
University of California, San Diego
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Roswell Park Cancer Institute
German CLL Study Group
University of Washington
Ohio State University Comprehensive Cancer Center
SCRI Development Innovations, LLC
Mayo Clinic
National University Hospital, Singapore
Mayo Clinic
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Targazyme, Inc.
University of Rochester
Arbeitsgemeinschaft medikamentoese Tumortherapie
M.D. Anderson Cancer Center